43.67
+0.55(+1.28%)
Currency In USD
| Previous Close | 43.12 |
| Open | 42.86 |
| Day High | 44.62 |
| Day Low | 42.86 |
| 52-Week High | 98 |
| 52-Week Low | 30.01 |
| Volume | 51,700 |
| Average Volume | 138,996 |
| Market Cap | 409.11M |
| PE | -4.64 |
| EPS | -9.42 |
| Moving Average 50 Days | 55.28 |
| Moving Average 200 Days | 51.13 |
| Change | 0.55 |
If you invested $1000 in Korro Bio, Inc. (KRRO) since IPO date, it would be worth $63.75 as of December 21, 2024 at a share price of $43.67. Whereas If you bought $1000 worth of Korro Bio, Inc. (KRRO) shares 3 years ago, it would be worth $160.26 as of December 21, 2024 at a share price of $43.67.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Korro to Participate in Upcoming Investor Conferences
GlobeNewswire Inc.
Nov 21, 2024 9:01 PM GMT
CAMBRIDGE, Mass., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent dis
Korro Receives Australian HREC Approval and CTN Clearance to Initiate Phase 1/2a Clinical Study (REWRITE) of KRRO-110 for Alpha-1 Antitrypsin Deficiency
GlobeNewswire Inc.
Nov 21, 2024 12:30 PM GMT
-REWRITE study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple escalating doses of KRRO-110 -First participant dosing anticipated in the first quarter of 2025 -Interim readout expected in second ha
Korro to Present at the Jefferies London Healthcare Conference
GlobeNewswire Inc.
Nov 14, 2024 1:00 PM GMT
CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today an